Corporate Presentation August 2020 OTCQB: INVO

OTCQB: INVO

Corporate PresentationAugust 2020

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

For Safety and Efficacy information: https://invobioscience.com/wp-content/uploads/2018/11/P-008_INVO-IFU-Nov-2018.pdf

FORWARD LOOKING STATEMENTS

2 | INVO Bioscience

INVO has created the INVOcellan FDA-cleared Device

A disruptive and novel fertility treatment option compared to traditional Intrauterine Insemination (IUI) and In-Vitro Fertilization (IVF)

COMPANY HIGHLIGHTS

4 | INVO Bioscience

FDA Cleared; CE Mark; Patented Device

$17-$20 Billion Industry Growing at

8-10% Annually

Pivotal U.S. Commercialization

Agreement with Industry Leader (Ferring

Pharmaceuticals)

Vast Underserved Global Market 95%+ of Infertile Individuals go

Untreated

Significant Unmet Market Opportunity

INVOcell Addresses Critical Industry

Challenges Regarding Treatment Cost &

Capacity Constraints

Ability to Help Treat Underserved Patients

Commercialization Internationally, with

Recent Distribution & JV Agreements Signed

199% Revenue Growth in 2019

Source: Allied Market Research, Grandview Research, CDC

THE INVOcell SYSTEM

5 | INVO Bioscience

CULTURE DEVICE

RETENTION DEVICE

The culture device holds the eggs and sperm. It is about

1.5 inches tall and just over 1 inch wide.

The retention device, with the culture device in it, is then

placed in the vaginal cavity.

INNER CHAMBEREggs & sperm are placed in the

inner chamber of the culture device

1.5”

1”

THE INVO PROCEDURE

6 | INVO Bioscience

INVOcell is the first intravaginal culture (IVC) device used for the incubation of eggs and sperm during fertilization and early embryo development

Uses the women’s body for natural incubation as an alternative to traditional in-vitro fertilization (IVF) that uses incubators for fertilization and embryo development

IUI was reported tohave an 8-10% rate of clinical

pregnancy success

Retrospect data reflected a~52.1% clinical pregnancy success

rate (SART 2018)*

Retrospect data reflected a~53.6% clinical pregnancy success

rate (SART 2018)

INVOcell SUCCESS – PATIENT OUTCOMES

7 | INVO Bioscience

INVOcell (IVC)

~52.1%SUCCESS

IUI

8-10%SUCCESS

IVFNo PGT

~53.6%SUCCESS

Infertility Treatment Options

INVO incubation period is country specific and is indicated for 3-5 days. In the US, the INVOcell Culture Device and Retention Device is not indicated for incubation periods exceeding 72 hours. FDA has not approved or cleared the product as safe and effective for use for incubation periods exceeding 72 hours (off -label). The Company has not studied the safety or efficacy of the device for incubation periods exceeding 72 hours and potential risks of off -label use is unknown. Reference US Instructions for Use (IFU) at https://www.invocell.com/hcp/wp-content/uploads/sites/6/2019/04/INVOcell-Instructions-For-Use-Booklet_R9-1.pdf.

*Source: ESHRE, SART May 17-19, 2020https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?reportingYear=2017#patient-first-attempt

SIGNIFICANTLY UNDERSERVED MARKET

8 | INVO Bioscience

7% - 15% Estimated percentage of reproductive age women

experiencing infertility worldwide

~2.5 MIVF cycles performed

worldwide

<5%Large underserved patient

base with only a small percentage receiving care

Served Underserved

Over 95% of the infertile couples remain untreated resulting in a significant unmet market opportunity.

Source: ASRM, SART, CDC

INDUSTRY CHALLENGES

9 | INVO Bioscience

INVOcell Helps Address Two Key Infertility Industry Challenges

Treatment Costs► Relative high costs for IVF treatment – reduces

affordability for many

Infrastructure and Capacity Constraints► Limited number of IVF clinics – and clustered in

population centers, which drives up costs for patients in rural areas

► Clinic throughput (volume limits) – lab capacity limitations

► Industry simply does not have enough capacity to handle the needs

$17-20 BillionThe global infertility market is estimated to be $17-20 billion

Growing at 8–10% per year

Source: Allied Market Research, Grandview Research, CDC

Analysis indicates that a 50% reduction in the price of IVF services would translate into a 160% increase in utilization of such services.

KEY BARRIERS TO TREATMENT: COST

10 | INVO Bioscience

1.5 1.5

2.4

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

Current # of WW IVF Procedures Implied Growth in IVC Based on Cost/Benefit

# of

IVF/

IVC

Proc

edur

es (i

n M

illio

ns)

Cost Has Been Identified As The #1 Barrier To Utilization Of IVF

Source: Chambers, Georgina M. et al. "The Impact Of Consumer Affordability On Access To Assisted Reproductive Technologies And Embryo Transfer Practices: An International Analysis". Fertility and Sterility 101.1 (2014): 191-198.e4. Web.


HOW DOES INVOcell SAVE COSTS?

LESS LABORATORYSPACE NEEDED

FEWERULTRASOUNDS

FEWERAPPOINTMENTS

LESS MEDICATION

Fertilization, Conception And Embryo Development Occur Inside The Body Not In A Laboratory

NATURALINCUBATION

PATIENTSAVINGS

Traditional IVFtreatment with medication

$12,000 - $15,000 PER CYCLE*

VS

$5,000 - $9,000PER CYCLE*

INVOcell IVC treatment with medication

* Excluding optional add-on’s (ICSI, Egg Freezing, Genetic Testing)


PATIENT ADVANTAGES

INVOcell

Equivalent Pregnancy Rates

Low Cost Per Cycle

Improved Accessibility To Treatment

Natural And Emotionally Connected Experience

Reduced Risk Of Lab Mistakes

Fewer Drugs – Lower Stimulation

COMMERCIALIZATION

MULTI-PRONGED COMMERCIALIZATION STRATEGY


DISTRIBUTION JOINT VENTURE

► Potentially upfront rights fee

► INVO Bioscience to supply INVOcell device at predetermined pricing

► Country/region exclusivity likely

► Minimum purchase obligations

► Partner with operator to create dedicated INVOcell Clinics

► INVO Bioscience to provide the device, training and general technology/lab support

► JV partner will be responsible for the operations of the INVOcell clinics, including entire IVC process

► U.S. and International

U.S.: FERRING DISTRIBUTION


Ferring Pharmaceuticals Commercialization AgreementJanuary 2019

► INVO Bioscience and Ferring Pharmaceuticals entered into an exclusive U.S. license and distribution/supply agreement for INVOcell® – Executed in January 2019.

► $5M up front payment received upon signing; $3M additional payment due upon completion of specific milestone (5-day label enhancement); supply agreement

► Ferring will be responsible for all U.S. commercial activities for INVOcell, excluding opportunities INVO Bioscience retains to establish INVO-only clinics.

► Ferring is required to purchase annual minimum device quantities from INVO in order to maintain U.S. exclusivity during the 7-year term.

► INVO Bioscience will be responsible for manufacturing and supplying product to Ferring.

Market = ~ 284,000 IVF Cycles per Year

AFRICA/EURASIA: DISTRIBUTION


Africa/EurasiaDistribution AgreementsQ4 2019

► INVO Bioscience entered into commercialization agreements in the continent of Africa with G-Systems covering Nigeria, and Quality Medicine covering Uganda, Sudan and Ethiopia. Following standard administrative requirements by each company to begin supplying INVOcell in the country, the Company believes distribution will commence in 2020. Each agreement includes minimum annual purchase requirements.

► INVO Bioscience entered into distribution agreements with OrcanMedical for Turkey, a leading medical distributor to large medical device companies including St. Jude Medical, Cooper Surgical, and Clarus, within the country. Orcan Medical will become the exclusive commercial partner for INVOcell in Turkey, contingent upon minimum purchase and other requirements.

► INVO Bioscience entered into distribution agreements with Biovate covering Jordan. Biovate will act as the exclusive distribution partner for INVOcell in the country following standard administrative requirements to begin supplying INVOcell in the country.

~ 125,000 IVF Cycles per Year

INDIA: MEDESOLE JOINT VENTURE


Medesole Healthcare and Trading Pvt LtdJoint VentureJanuary 2020

► INVO Bioscience and Medesole entered into joint venture to operate dedicated INVOcell clinics in India in January 2020.

► Under terms of the agreement, INVO Bioscience and Medesole will each own 50% of the joint venture. INVO Bioscience will provide the device, training and general technology support to the joint venture, while Medesole will be responsible for the operations of the INVOcell clinics in India. Both partners will equally invest in start-up and capital expenditures and share in the revenue and profits of the joint venture.

► Medesole INVO Bioscience Private Limited, has set an initial objective of opening three INVOcell clinics over the next 12 months, with additional clinics planned in subsequent years. Based on the initial first year plan, INVO Bioscience anticipates it will invest approximately $150,000 to $200,000 in the JV. Subsequent investments will be based on JV performance and mutual agreements between INVO Bioscience and Medesole.

~ 110,000 IVF Cycles per Year

KEY INTERNATIONAL TARGET MARKETS


China

► Active Discussions► JV-Type Focus► ~700,000 IVF Cycles Per Year

Europe

► Multiple Markets In Discussion► Various Types► ~700,000 IVF Cycles Per Year

► Active Discussions ► Partnership

Mexico

► Multiple Markets In Discussion ► Various Types

South America

► Multiple Markets In Discussion► Various Types

Other Southeast Asia

► Registration Underway ► Seeking Partner► ~450,000 IVF Cycles Per Year

Japan

LABEL EXPANSIONOPPORTUNITY TO RECEIVE $3 MILLION MILESTONE PAYMENT


Expand INVOcell Label to 5-day Incubation

In February 2020, IRB approval to begin clinical pivotal trial ► Single arm, multicenter, open label trial at three clinical sites in the United States

with each site enrolling 60 patients between the ages of 18 and 37 years old.

Align marketing with current standard IVF treatment

Update INVOcell clinical success rate

Receive $3 million milestone payment from Ferring

Expand currently approved label from 3-day incubation to 5-day incubation

KEY ACCOMPLISHMENTS AND 2020 GOALS


Recent Accomplishments 2020 Goals

Signed major U.S. commercialization agreement

Expand international business development team

Expand regulatory clearance in key countries, including CE Mark

Sign first major international distribution agreements

Sign first joint venture agreement to open INVOcell clinics

Diversify and expand revenue base with a goal to more than double product revenues

Open first INVOcell clinics

Complete 5-day label Clinical Study

Sign additional major international agreements (JV or distribution)

Continue to improve Public Company profile and overall investor base

REVENUE


$11,689 $50,901

$282,145

$494,375

$1,480,213

$504,643

$0

$200,000

$400,000

$600,000

$800,000

$1,000,000

$1,200,000

$1,400,000

$1,600,000

2015 2016 2017 2018 2019 YTD 6 Mo 2020


INCOME STATEMENTConsolidated Statement of Operations

For the Six For the Twelve For the Twelve For the Twelve For the Twelve For the TwelveMonths Ended Months Ended Months Ended Months Ended Months Ended Months Ended

June 30, December 31, December 31, December 31, December 31, December 31,2020 2019 2018 2017 2016 2015

Revenue:Product Revenue $ 147,500 $ 765,927 $ 494,375 $ 282,145 $ 50,901 $ 11,689 License Revenue $ 357,143 $ 714,286 $ - $ - $ - $ -

Total Revenue $ 504,643 $ 1,480,213 $ 494,375 $ 282,145 $ 50,901 $ 11,689

Cost of sales 51,164 139,670 90,367 51,954 15,094 7,810

Gross margin 453,479 1,340,543 404,008 230,191 35,807 3,879

Selling, general and administrative expenses 2,847,985 3,128,635 3,038,068 870,612 2,146,221 598,953 Research and development costs 64,940

Total Operating Expenses 2,912,925 3,128,635 3,038,068 870,612 2,146,221 598,953

Loss from Operations (2,459,446) (1,788,092) (2,634,060) (640,421) (2,110,414) (595,074)

Total other expenses 307,827 379,019 442,031 61,742 13,838 4,364,173

Income (Loss) before income taxes (2,767,273) (2,167,111) (3,076,091) (702,163) (2,124,252) (4,959,247)

Provision for income taxes - - - - - -

Net Loss $ (2,767,273) $ (2,167,111) $ (3,076,091) $ (702,163) $ (2,124,252) $ (4,959,247)

Basic net loss per weighted average shares of common stock $ (0.01) $ (0.02) $ (0.02)$ (0.00) $ (0.02) $ (0.04)

Diluted net loss per weighted average shares of common stock $ (0.01) $ (0.02) $ (0.02)$ (0.00) $ (0.02) $ (0.04)

Basic weighted average number of shares of common stock 7,880,751 7,767,805 7,366,653 7,065,253 6,959,828 6,428,381

KEY STATISTICS


INVO Bioscience (OTCQB: INVO) Data as of 8/17/2020

Market Cap $28 million

Stock Price | 52-Week Range $3.54 | $1.75 - $8.55

Basic Shares Outstanding 7.9 million

FD Shares Outstanding 9.4 million (assuming conversion of convertible debt and all warrants and vested options)

Management Ownership ~17%; ~32% when including founder/affiliate

Free Trading Shares ~3.0 million

Cash (6/30/20) $1.5 million*

*Subsequent to the quarter end, the Company completed its 3rd and final closing of its convertible note financing along with the receipt of its PPP loan, the combination of which added approximately $557,000 in additional cash proceeds.


INVESTMENT RECAP

INDUSTRY

PRODUCT

Commercialization

► Multi-billion dollar, large and growing global market opportunity

► Significantly underserved market

► Revolutionary, FDA-cleared device, that we believe is a major breakthrough in the fertility industry.

► High margins

► Commercialization efforts greatly enhanced with recently-signed partnership with Ferring, a multi-billion pharma company; along with large international opportunities

MANAGEMENT


Steven M. ShumChief Executive Officer and DirectorRecently served as Chief Financial Officer of Eastside Distilling (NASDAQ: EAST) since October 2015. Prior to joining Eastside, Mr. Shum served as an Officer and Director of XZERES Corp, a publicly-traded global renewable energy company, from October 2008 until April 2015 in various officer roles, including Chief Operating Officer from September 2014 until April 2015, Chief Financial Officer, Principal Accounting Officer and Secretary from April 2010 until September 2014 (under former name, Cascade Wind Corp) and Chief Executive Officer and President from October 2008 to August 2010.

Michael J. CampbellCOO and Vice President of Business Development and DirectorMost recently the Vice President of IVF Americas Business Unit for Cooper Surgical, Inc. (CSI), a wholly owned subsidiary of The Cooper Companies (NYSE: COO). Mr. Campbell has substantial medical device sales, marketing and business development leadership experience within Global Fortune 500 and Start-up Company environments.

Christopher MyerVice President of Business Development - AmericasMr. Myer most recently served for four years in the Fertility and Genomics Group at CooperSurgical, Inc as Director, Corporate Accounts and Strategic Relationships – North America; and was previously Regional Sales Director, Fertility & Genomics Business Unit in the mid-Atlantic and Southeast region of the U.S. Mr. Myer also worked at leading medical device and capital equipment companies including Alliance Healthcare and McKesson Corporation.

Kevin Doody MDMedical Director and DirectorRenowned fertility specialist who is the founder and Medical Director for the Center for AssistedReproduction (CARE Fertility) and Effortless IVF located in Bedford Texas. Dr. Doody is President of theSociety for Assisted Reproductive Technology (SART), on the Board of Directors of the American Society forReproductive Medicine (ASRM) and a member of the RESOLVE Physician Council.

Kathleen KarloffChair of Board and former CEOOver 30 years of experience in medical device and pharmaceutical manufacturing, clinical operations, regulatory affairs and quality systems with 13 years at Boston Scientific and 18 years on the senior management teams of start-up organizations.

Pressly AhammedDirector of International Business DevelopmentHas worked over the last 11 years in numerous segments of the international healthcare sector including hospitals; wholesale and retail sectors; and distribution. Ahammed joined INVO Bioscience from Cooper Surgical, where he held a similar title focused on women's healthcare business development in Eastern Europe, the Middle East, Africa, and South and Central Asia.

Inger Britt Carlsson, PhDVice President of Global Medical AffairsWith over 30 years' experience in the fertility industry, Dr. Carlsson was most recently Global Director of Medical Affairs for CooperSurgical Fertility and Genomics. Prior to CooperSurgical, she was Associate Director-Medical Affairs for EMD Serono from 2014 to 2015. She has also served as Medical Science Liaison-Medical Affairs for Sanofi Aventis (formerly Genzyme) and Medical Science Liaison-Women's Health for Merck (formerly Schering-Plough).

Yve LyppensDirector Business Development - Asia PacificJoined INVO with more than a decade of experience in sales and distribution management. From 2016 to the present, he served as Asia Pacific Sales Director for Biomedic Hong Kong Ltd., a medical device distributor in Mainland China. Prior to that, from 2011 to 2016, Mr. Lyppens served as a Director, Shareholder and Sales Manager at F Care Systems Hong Kong Ltd., a developer and exporter of medical aesthetics equipment.

PATENTS & APPROVALS


► Container assembly for intravaginal fertilization and culture and embryo transfer and method of intravaginal culture employing such a container► Europe, China, and Japan

► Incubation and/or storage container system and method► Patent #US 7,759,115. Additional patents pending► US, Europe, UK, France, Germany, Russia and India

► Registrations► United States

► FDA Clearance of De Novo Class II device in November 2, 2015► Canada

► Health Canada approved► Europe

► CE Mark (received Oct 2019)► India

► Product registered► Brazil

► ANVISA approved► Colombia

► New INVIMA in process► Mexico

► Registration in process.

APPENDIX

PROCESS

INVOcell Laboratory ProcessIVF Laboratory Process

Aikani M, et al. 2014 Fert and Stert VOL. 102 NO. 5


ASRM STAFFING GUIDELINES

Traditional IVF INVO (IVC)

2000 Cycles = 11 Embryologists (2008 recommendations)

New Recommendations is 1 per 100 cycles:2000 Cycles would require 20 embryologists

2000 Cycles = 1.5 Embryologists


IVC = More Efficient Lab

INVO Center Lab Traditional IVF Lab


AMERICAN INSTITUTE OF REPRODUCTIVE MEDICINE (AIRM) – A Case Study

2017• AIRM Opened in Birmingham

Alabama offering IVF and IVC

2019• Started IVC only late 2018• Attract(s) patients from 20

States• 350 cycles 2019

2020• Will do 11 “Batches” of IVC

with approx. 60-70 patient per batch

• Trending to 700+ Cycles 2020• Did not affect volumes of

traditional IVF clinic 2 floors above in same building


ARE THERE LIMITATIONS TO INVOCELL?


IVF INVOcell

ICSI

Perform ICSI

PGT (A,SR,M)

Run any genetic testing prescribed

AI Process

Life Whisperer (embryo grading)Oocyte grading

Sperm Analysis

HBA AssayPICSIZymot

Witnessing

Electronic witnessing (Matcher, RI Witness)

Documents

Corporate Presentation August 2020 OTCQB: INVO